Pictet Asset Management Holding SA Sells 55,700 Shares of Sanofi (NASDAQ:SNY)

Pictet Asset Management Holding SA lowered its holdings in Sanofi (NASDAQ:SNY) by 7.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 733,291 shares of the company’s stock after selling 55,700 shares during the period. Pictet Asset Management Holding SA’s holdings in Sanofi were worth $35,367,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in SNY. Boston Partners raised its position in Sanofi by 86.4% during the fourth quarter. Boston Partners now owns 5,396,531 shares of the company’s stock worth $260,607,000 after acquiring an additional 2,501,073 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of Sanofi by 13.1% in the third quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock valued at $208,106,000 after buying an additional 395,744 shares during the last quarter. Magnetar Financial LLC boosted its stake in shares of Sanofi by 104.3% during the 4th quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company’s stock worth $161,103,000 after acquiring an additional 1,705,148 shares during the period. Natixis Advisors LLC increased its holdings in shares of Sanofi by 1.2% during the 4th quarter. Natixis Advisors LLC now owns 2,910,021 shares of the company’s stock worth $140,350,000 after acquiring an additional 35,828 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in Sanofi in the 4th quarter valued at $135,933,000. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on SNY shares. The Goldman Sachs Group initiated coverage on shares of Sanofi in a research report on Friday, March 21st. They set a “neutral” rating and a $65.00 price objective for the company. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Finally, StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Three research analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Sanofi currently has a consensus rating of “Moderate Buy” and an average target price of $62.50.

Sanofi Price Performance

NASDAQ:SNY opened at $55.82 on Monday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. Sanofi has a 52 week low of $45.22 and a 52 week high of $60.12. The firm’s 50-day simple moving average is $55.13 and its 200 day simple moving average is $52.76. The firm has a market cap of $141.66 billion, a price-to-earnings ratio of 22.42, a P/E/G ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, sell-side analysts predict that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.